Other Publications Referenced in Amarin’s Investor Communications

To search publications using the available search words, please click here:

The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction.

Wang X, Verma S, Mason RP, Bhatt DL. The road to approval: a perspective on the role of icosapent ethyl in cardiovascular risk reduction. Curr Diabetes Rep. 2020;20:65. https://link.springer.com/content/pdf/10.1007/s11892-020-01343-7.pdf

cholesterol

data monitoring committee

diabetes

icosapent ethyl

New insights into icosapent ethyl for patients with residual cardiovascular risk.

Radenkovic D, Olshansky B, Bhatt D. New insights into icosapent ethyl for patients with residual cardiovascular risk. EMJ Cardiol. 2020;8:34-40. https://www.emjreviews.com/cardiology/symposium/new-insights-into-icosapent-ethyl-for-patients-with-residual-cardiovascular-risk/

Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside.

Bhatt DL. Mechanisms of action, efficacy, and safety of icosapent ethyl: from bench to bedside. Eur Heart J. 2020;22(Supplement J):J1-J2. https://doi.org/10.1093/eurheartj/suaa114

Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap.

Parhofer KG, Chapman MJ, Nordestgaard BG. Efficacy and safety of icosapent ethyl in hypertriglyceridaemia: a recap. Eur Heart J. 2020;22(Supplement J):J21-J33. https://doi.org/10.1093/eurheartj/suaa116

Investor Relations / Publications / Other Publications Referenced in Amarin’s Investor Communications

Other Publications Referenced in Amarin’s Investor Communications

Amarin Corporation